eGenesis, a Cambridge, Mass.-based gene-editing and genome-engineering company developing human-compatible organs, tissues, and cells, completed a $125m Series C financing.
Backers included Farallon Capital Management, Polaris Partners, HBM Healthcare Investments, Invus, Samsara BioCapital, LifeSci Venture Partners, Irving Investors, Catalio Capital Management, SymBiosis, Altium Capital, Monashee Investment Management, and Osage University Partners and existing investors Leaps by Bayer, Fresenius Medical Care Ventures, ARCH Venture Partners, Wellington Partners, Khosla Ventures, and Alta Partners. In conjunction with the closing of the financing, Isaac Ciechanover, MD, from Polaris Partners, and Mark Pruzanski, MD, Founder and former Chief Executive Officer of Intercept Pharmaceuticals, joined the eGenesis Board of Directors.
The company intends to use the funds to bring its lead programs in kidney and islet cell transplant into human proof-of-concept studies and continue to develop its proprietary gene-editing platform and scaling of GMP production.
Led by Paul Sekhri, President and Chief Executive Officer, eGenesis aims to offer safe and effective organs, tissues, and cells to patients in need. The company harnesses gene editing technologies to address the key issues that have impeded xenotransplantation to date. Its development pipeline includes lead programs for kidney and islet cell transplant as well as earlier-stage programs focused on other solid organs.